# 9-ME-BC + Methylene Blue (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/9-me-bc-plus-methylene-blue-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A powerful dopaminergic nootropic combined with a mitochondria-targeting electron carrier for enhanced cognitive function.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/9-me-bc-plus-methylene-blue-capsule

\*\*9-Methyl-β-carboline + Methylene Blue\*\* — A powerful dopaminergic nootropic combined with a mitochondria-targeting electron carrier for enhanced cognitive function. \*\*Category:\*\* Cognitive & Neuro · \*\*Status:\*\* Research Only ### Description 9-ME-BC (9-Methyl-β-carboline) is a β-carboline alkaloid that promotes dopamine neuron growth, survival, and function through multiple neuroprotective mechanisms. It was identified in research as a compound capable of stimulating dopaminergic neurogenesis — the growth of new dopamine-producing neurons — making it of significant interest in neurodegenerative disease research. Methylene Blue, the second component, is a phenothiazine dye with well-documented mitochondria-targeting properties that has been used in medicine for over a century. In the brain, Methylene Blue acts as an alternative electron carrier in the mitochondrial respiratory chain, improving ATP production efficiency and reducing the formation of reactive oxygen species. Together, these two compounds address both the dopaminergic and bioenergetic dimensions of cognitive function, making this combination a subject of active nootropic research. ### Key Characteristics - \*\*Molecular Weight:\*\* Not specified - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily ### Investigated Benefits - Enhanced dopaminergic function - Improved cognitive performance - Mitochondrial energy optimization - Neuroprotection - Potential neurogenesis \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action 9-ME-BC inhibits both MAO-A and MAO-B (monoamine oxidase enzymes), reducing dopamine degradation and increasing synaptic dopamine availability. It also upregulates tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, and promotes BDNF expression to support neuronal survival and plasticity. Methylene Blue acts as a redox cycler in the mitochondrial electron transport chain — accepting electrons from NADH and passing them to cytochrome c, effectively bypassing Complex I/III dysfunction. This improves ATP production, reduces oxidative stress, and has been shown to enhance memory consolidation in animal models. The combined action of dopaminergic enhancement (9-ME-BC) and mitochondrial optimization (Methylene Blue) produces synergistic cognitive benefits that neither compound achieves alone. ### Dosing & Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily - \*\*Cycle Length:\*\* 4–8 weeks - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Take in the morning. Methylene Blue may cause blue-green urine (normal). Avoid with MAOIs or serotonergic drugs. ### Storage Information Store at room temperature, away from light. ### Quality & Sourcing Standards When sourcing 9-ME-BC + Methylene Blue (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. 9-ME-BC demonstrated dopaminergic neuroprotection in animal models 2. Methylene Blue shown to improve cognitive function in human studies 3. Mitochondrial enhancement demonstrated for Methylene Blue ### Evidence Level \*\*Preliminary Evidence\*\* — Early-stage research only. Significant uncertainty about efficacy and safety in humans. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.